ORGOVYX™ (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., January 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Myovant Sciences as a specialty pharmacy provider for ORGOVYX™ (relugolix) for the treatment of advanced prostate cancer. ORGOVYX, approved by the U.S. Food and Drug Administration (FDA) on December 18, 2020, is an […]